Purpose This study aimed to investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which are volume-based PET parameters, using 18 F-2-fluoro-2-deoxy-D-glucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) in patients with surgically resectable lung adenocarcinoma. Methods We retrospectively evaluated 149 patients with lung adenocarcinoma who underwent 18 F-FDG PET/CT before surgical resection. Maximum standardized uptake value (SUVmax), MTV, and TLG of the primary tumor with threshold value of SUVmax 30, 40, and 50% were calculated, respectively. To compare the predictive performance of volumebased PET parameters, recurrence-free survival was assessed using the Kaplan-Meier method. Results The study included 70 males and 79 females with an average age of 65.8 years. The median follow-up time was 45.4 months. Recurrence was observed in 53 patients (35.6%). The mean ± SD SUVmax, MTV 30% , and TLG 30% of the entire cohort were 4.79 ± 2.94, 19.45 ± 24.85, and 56.43 ± 101.88, respectively. The cut-off values of MTV 30% and TLG 30% for recurrence were 11.07 ad 30.56, respectively. The 1-year recurrence-free survival (RFS) rate was 96.5% in low-MTV 30% patients compared with 86.2% in high-MTV 30% patients (p = 0.018) and 96.0% in low-TLG 30% patients compared with 88.5% in high-TLG 30% patients (p < 0.001). On univariate and multivariate analysis, TLG 30% (HR, 2.828, p < 0.001; HR, 2.738, p < 0.001, respectively) was an independent prognostic factor for predicting recurrence-free survival (RFS). Conclusion TLG 30% value was observed to be a significant prognostic factor for RFS in patients with lung adenocarcinoma treated by surgical resection.
Introduction
Lung cancer is one of the most common cancers in both men and women and the most common cause of cancer-related death in the world [1, 2] . Non-small cell lung cancer (NSCLC) accounts for up to 85-90% of all lung cancer cases. Patients with stage I and II and selective stage III NSCLC are considered eligible for curative surgical resection with complete lymph node dissection. After complete surgical resection, however, a large number of patient experience recurrence (with a 5-year recurrence rate up to 39.6%) and die [3, 4] . Loco-regional recurrence and distant metastases are the most common causes of treatment failure [5, 6] . High TNM stage Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13139-018-0555-4) contains supplementary material, which is available to authorized users.
has been considered a poor prognostic factor in patients with NSCLC. Furthermore, considerable number of patient experience relapse after curative treatment despite low-stage disease status, and up to 25% of patients with stage I NSCLC experience relapse after surgical resection. Because patients with the same disease stage could have diverse tumor-and patientspecific prognostic factors, it is necessary to take into consideration these factors for determining the individual therapeutic strategy [7, 8] . 18 F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) is one of the important imaging modalities for staging, determining treatment strategy, and predicting the prognosis of NSCLC. 18 F-FDG PET parameters such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) can provide useful data to understand tumor metabolic activity. 18 F-FDG PET parameters have been studied as potential prognostic factors. The SUVmax is the most commonly used FDG PET parameter because of its reproducibility and availability. SUVmax is the value of a single voxel with the highest radiotracer activity within the region of interest (ROI) of the tumor, whereas volume-based parameters MTV and TLG represent the metabolic tumor burden. There has been interest in the clinical significance of volume-based parameters for NSCLC. Studies have reported that MTV and TLG showed better performance for predicting the prognosis compared with SUVmax in high stage III and IV NSCLC [9, 10] . In patients with NSCLC treated by surgical resection, MTV and TLG showed better predictive performance compared with SUVmax for recurrence-free survival (RFS) and overall survival (OS). MTV 2.5 (measured by using the lowest threshold value of SUV2.5) was reported as a significant prognostic factor for OS [11] . However, there were no significant different in RFS among MTVs and TLGs that were calculated according to various thresholds of SUVs (2.5, 3.0, 3.5, 4.0). Furthermore, recent studies have shown that TLG was also a significant prognostic factor for predicting RFS and OS in early stage I NSCLC [12] . The most recent study reported the prognostic value of MTV in patients with stage I NSCLC treated by surgical resection [13] .
NSCLC comprise several histologic subtypes, which include adenocarcinoma and squamous cell carcinoma. Studies have reported that SUVmax, MTV, and TLG were significantly lower in adenocarcinoma that in squamous cell carcinoma patients and adenocarcinoma had a worse prognostic outcome compared with squamous cell carcinoma based on the potential to metastasize [14, 15] . This finding may have an important influence on the interpretation of 18 F-FDG PET scans of patients with these two NSCLC subtypes. Based on the results of these previous studies on the metabolic characteristics of adenocarcinoma and other histologic subtypes and the prognostic value of volume-based PET parameters, we hypothesized that volume-based PET parameters using lower threshold values can show better performance for predicting prognosis in lung adenocarcinoma patients.
The aim of this study is to investigate the prognostic value of volume-based PET parameters MTVs and TLGs using various threshold values (30, 40 , and 50%) of SUVmax in patients with lung adenocarcinoma who underwent surgical resection and to ascertain the optimal threshold value to calculate the MTV and TLG to predict the recurrence.
Materials and Methods

Patients
This study was a retrospective review of lung cancer database at our hospital using data collected between January 2010 and December 2015. The inclusion criteria for this study required patients to have the following: (1) histologically proven lung adenocarcinoma, (2) a histopathologic confirmed mediastinal lymph node stage, and (3) treated with curative-intent surgical resection. Patients with stage I and II and selective stage III lung adenocarcinoma with diagnosis based in the 7th edition TNM classification after surgical resection and complete lymph node dissection were enrolled. Patients who met the following criteria were excluded: (1) any chemotherapeutic or radiotherapeutic treatments before the 18 F-FDG PET/CT scan, and (2) other pre-or coexisting primary malignancy. The study protocol for this retrospective study was reviewed and approved by institutional review board at our institution (2018AN0195).
Clinical Follow-up
We retrospectively reviewed the medical records, and pathologic data. Chest computed tomography (CT), 18 F-FDG PET/ CT, and endobronchial ultrasound bronchoscopy were performed preoperatively. Surveillance of recurrence was performed primarily using imaging modalities. Postoperatively, chest CT scans were obtained at 3-month intervals and PET/ CT scans were also obtained to detect recurrence. Recurrence was determined using primarily physician clinical assessment, radiographic reports, and/or review of imaging studies. For cases suspected to have recurrence, we additionally performed invasive procedures including CT-guided needle biopsy or bronchoscopic biopsy to support the clinical diagnosis. Local recurrence was defined as recurrence occurring on the resection margin or bronchial stumps. Regional recurrence was defined as recurrence occurring in the ipsilateral lung; mediastinal, hilar, and supraclavicular lymph nodes; or pleural cavity. Distant metastases were defined as lesions occurring in the contralateral lung, adrenal glands, brain, liver, bone, or other organs. F-FDG PET/CT was performed using Gemini TF (Philips Medical Systems, Cleveland, OH, USA). All patients fasted for 6 h and had serum glucose levels < 140 mg/day before the scan. CT scans were obtained followed by PET for 1 min/bed 1 h after an intravenous injection of 370-555 MBq 18 F-FDG according to body weight. The PET unit had an 18-cm axial fields of view and 4.4-mm spatial resolution. A low-dose CT scan was obtained for attenuation correction and localization on a 16-slice multi-detector helical CT (120 kVp; 50 mA; 0.75-s rotation time; 0.75-mm slice collimation; 4-mm scan reconstruction, with a reconstruction index of 4 mm; 512 × 512 matrices). The PET data acquired from the thigh to head for 1.0 min per frame were reconstructed iteratively using a three-dimensional row action maximum likelihood algorithm (RAMLA) with low-dose CT data sets for correcting attenuation.
Measurement of PET Parameters
PET parameters were determined using a dedicated workstation (Extended Brilliance Workspace 4.0 with a PET/CT viewer for automated image registration, Philips, Amsterdam, The Netherland). We reviewed all the available clinical information, and interpreted the PET/CT image. We measured the MTVs and TLGs of malignant lung lesions with semiautomatic method. After reviewing the margin and shape of the malignant lung lesion through chest CT image, we drew spherical shape of volume of interest (VOI) on PET scan image, which included over gross tumor volume on CT image. Within drown VOI, the MTVs were automatically calculated using an isocontour method with variable threshold values. The SUVmax was defined as the voxel with the highest count within the VOI. The MTV 30% , MTV 40% , and MTV 50% were defined as a volume greater than a fixed threshold of 30, 40, and 50% of the maximum intratumoral activity, respectively. Additionally, we measured the MTV and TLG with fixed threshold value, SUV2.0. Representative cases of measuring MTV 30% and TLG 30% are shown in Fig. 1 . In Fig. 1a , a 3.1-cm lesion in right lower lung (T1b, stage IB) showed mild FDG uptake with SUVmax 2.3, MTV 30% 15.3, TLG 30% 17.9. In Fig. 1b , a 3.6-cm lesion in right upper lung (T2a, stage IIB) showed mild FDG uptake with SUVmax 2.6, MTV 30% 29.5, TLG 30% 37.0.
Previous studies reported that a higher lymph node ratio correlated with poor prognostic outcome in NSCLC. We calculated the lymph node ratio (LNR) as the ratio between the number of positive N1 and N2 lymph nodes and the number of lymph nodes removed among all mediastinal lymph nodes during the surgery. Base on the prior studies, patients were divided into two groups: low-LNR ≤ 0.15 and high-LNR > 0.15 [16, 17] .
Statistical Analysis
Statistical analysis was performed using SPSS version 19.0 software (SPSS INC., Chicago, IL, USA). All p values < 0.05 were considered significant. Clinical parameters were described as means ± standard deviations of the mean for continuous variables and as frequencies (%) for categorical variables. Student's t test or Mann-Whitney U test and χ 2 test or fisher's exact tests were applied to compare the continuous and categorical variables, respectively.
The primary endpoint was RFS, which was measured from the date of the surgical operation to the date of recurrence. The Kaplan-Meier method was used to perform the survival analysis. Receiver operating characteristic (ROC) analysis was performed to calculate the area under the ROC curve (AUC) for each PET parameters. The log-rank test and Cox regression analysis were performed to evaluate the relationships between the categorical variables and RFS. Hazard ratios (HR) with 95% confidence intervals (CI) were determined in the multivariate Cox regression analysis.
Results
Patients Characteristics
Clinicopathologic characteristics of 149 patients are listed in Table 1 . Of the 149 patients who were evaluated retrospectively, 70 (49%) were male and 79 (53%) were female with a mean age of 65.81 ± 8.44 years. The median follow-up time was 45.4 months (range 3.0-99.6 months). One hundred forty-two (95.3%) patients underwent lobectomy and 7 patients (4.7%) underwent wedge resection. Forty-nine patients (32.9%) had a smoking history (ex-and current smoking). The mean number of dissected lymph nodes was 14.36 ± 7.61. The mean of whole tumor size was 2.93 ± 1.52 cm. Thirty-eight patients (25.5%) had lymph node metastasis; 17 (11.4%) were N1 and 21 (14.1%) were N2.
Preoperative PET Parameter Analysis
Among the 149 patients of the entire cohort, the mean SUVmax of primary tumor was 4.79 ± 2.94 (mean ± standard deviation). We performed a comparison analysis for the PET parameters between the non-recurrence group and the recurrence group ( ROC curve analysis was performed to define the optimal cut-off value of PET parameters for predicting recurrence (Table 3 ). In the ROC curve analysis, the AUC of TLG 30% for the recurrence was the highest compared with the AUCs of SUVmax, MTVs, and TLGs. MTVs and TLGs with a threshold value of 30% of SUVmax showed larger AUCs than those of MTVs and TLGs with a threshold value of 40%, and 50% of SUVmax. Therefore, we chose the MTV 30% and TLG 30% models to compare the prognostic value for predicting recurrence between MTV and TLG. The optimal cut-off value was 4.22 (sensitivity 60.4%, specificity 57.3%), 11.07 (sensitivity 62.3%, specificity 57.3%), and 30.56 (sensitivity 60.4%, specificity 57.3%) for SUVmax, MTV 30% , and TLG 30% , respectively; 74 patients (49.7%) showed SUVmax above 4.22, 73 patients (49.0%) showed MTV 30% above 11.07, and 60 patients (40.3%) showed TLG 30% above 30.56 (Table 3) . According to the cut-off values of MTV 30% and TLG 30% , we divided the entire patient cohort into two groups and performed the comparison analysis between the two groups (Table 4 ). There was a significant difference in stage between high-MTV 30% and low-MTV 30% groups (p < 0.001) and between the high-TLG 30% and low-TLG 30% groups (p = 0.020).
Recurrence-Free Survival Analysis
Recurrence was observed in 53 patients (35.6%) as follows: 20 cases of loco-regional recurrence (1 resection margin or bronchus, 5 pleura, 5 mediastinum, and 14 ipsilateral lung, with 6 cases involving two sites), and 33 case of distant metastasis (18 lung, 6 bone, 4 brain, 3 extrathoracic lymph nodes, 2 liver, 1 adrenal gland, and 1 spinal cord, with 16 cases of multiple metastases). The median RFS time was 35.4 months; Kaplan-Meier survival analysis showed that the 1-year, 2-year, and 5-year RFS rates were 92.4, 79.9, and 56.9%, respectively (Fig. 1a) . The 1-year RFS rate was 96.6% in low-MTV 30% patients compared with 86.2% in high-MTV 30% patients (p = 0.018, Fig. 1b ) and 96.0% in low-TLG 30% patients compared with 88.5% in high-TLG 30% patients (p < 0.001, Fig. 1c ).
Risk Factors for Recurrence-Free Survival
In univariate analysis, high LNR, high MTV 30% , high TLG 30%, advanced stage, and lymphovascular invasion were risk factors for RFS (Table 5 ). On analysis using the TLG 30% model, which included TLG 3 0 % , LNR, stage, and lymphovascular invasion, TLG 30% (HR 2.783; p < 0.001) and lymphovascular invasion (HR 10.006; p = 0.001) were the independent risk factors for RFS. On analysis of the MTV 30% model, which included MTV 30% , LNR, stage, and lymphovascular invasion, lymphovascular invasion (HR 8.865, p = 0.002) was observed to be the only independent risk factor for RFS, and MTV 30% showed marginal significance (HR 2.071; p = 0.059) (Fig. 2) .
Discussion
In this study, we found that TLG 30% value was an independent prognostic factor for RFS in patients with stage I-IIIA lung adenocarcinoma treated by surgical resection. Recurrence is one of most common causes of treatment failure in patients after surgery for NSCLC. Despite the early stage of NSCLC, up to 30% of NSCLC patients experience recurrence during follow-up, and this recurrence is strongly related to poor OS [3, 4] . It has been reported that several clinicopathologic prognostic factors such as sex (male), old age, high lymph node stage, lymphovascular invasion, and histologic grade were strongly correlated with poor RFS and OS [3, 6, 18, 19] . As reported in the literature, adenocarcinoma is the predominant histologic type in NSCLC [20] . There is a need for additional prognostic markers to identify patients who require adjuvant therapy for early-stage NSCLC after curative treatment. The latest National Comprehensive Cancer Network guidelines define that patients for high risk for poorly differentiated cancer, visceral pleural involvement, vascular invasion, tumor size > 4 cm, wedge resection, and unknown lymph node status [21] . These patients may be potential candidates for postoperative adjuvant chemotherapy. The prognostic value of volume-base PET parameters, which is independent of the TNM stage, has been widely studied in NSCLC [9] [10] [11] [12] [13] [22] [23] [24] [25] . MTV defines the volume of a metabolically active tumor, and TLG is measured by multiplying the MTV with the mean SUV; thus, an approach involving the use of MTV and TLG combines the volumetric and metabolic information of primary tumor lesion from 18 F-FDG PET. SUVmax may be a surrogate marker for tumor aggressiveness [26, 27] ; however, it could be affected by the biologic (serum glucose level, body weight, fasting time) and technologic factors (image acquisition time, reconstruction method). Tumor volume may be important not only in advanced-stage but also in early-stage NSCLC. Regarding the clinical significance of MTV and TLG in stage I lung adenocarcinoma, two recent studies have been reported. Wang et al. [13] reported that among SUVmax, SUVmean, SUVpeak, MTV, and TLG, only MTV was an independent prognostic factor for progression; this study analyzed stage I NSCLC in 127 patients and applied the 2 PET delineation methods according to different pulmonary nodule types. The methods used for solid lesions was adaptive target volume delineation using adaptive iterative algorithm; the method used for non-solid and part-solid lesions was adaptive thresholding at 40% SUVmax, which adapts the threshold value inside the selected VOI relative to the mean background SUV.
Park et al. [12] evaluated preoperative SUVmax and TLG in 248 patients with stage IA NSCLC that was treated by surgical resection; in multivariate analysis for OS using the SUVmax model and TLG model, the concordance index of the TLG model was slightly higher than that of the SUVmax model. They used the threshold value of SUV2.5 and analyzed only stage IA patients; thus, the small size of stage IA NSCLC lesions may have influenced the MTV by partialvolume effects. Even though these two studies analyzed stage I lung adenocarcinoma, the clinical implication of volumebased PET parameters was controversial. In addition, a fixed threshold value of SUV2.5 or 50% of SUVmax of the primary tumor were mainly used as the threshold intensity values [12, 28, 29] , and 40% of threshold values showed the best performance for defining the tumor volume [30] . We also analyzed the predictive value of recurrence with MTV . SUV2.0 as threshold value to calculate the MTV and TLG showed relatively high cut-off value in our study. Lung adenocarcinoma showed a significantly lower value of SUVmax, MTV, and TLG than those of squamous cell carcinoma [14, 15] ; we further analyzed the prognostic value of MTVs and TLGs using the lower threshold value of 30% of SUVmax of the primary tumor. Lung adenocarcinoma consists of various histologic subtypes. The predominant histologic subtypes of adenocarcinoma are acinar, lepidic, papillary, micropapillary, solid, and mucinous type. A recent study reported the differences in GLUT1 expression and the prognostic potential of FDG-PET according to the histologic subtypes of NSCLC. The micropapillary and solid histologic subtypes of lung adenocarcinoma were associated with GLUT1 expression, and high MTV and TLG values were associated with the solid histology. However, the majority of subtypes of adenocarcinoma in our study were acinar (57.5%). These histologic subtypes showed a relatively lower GLUT1 expression and 18 F-FDG uptake. In addition, micropapillary (5.7%) and solid (11.4%) histology constituted a lower proportion of entire cohort, respectively. This may be attributed to the effect of the lower value of MTVs and TLGs of the primary tumor in our entire cohort.
In a previous study, Kim et al. [11] reported that MTV was a better predictor for RFS and OS compared with TLG in NSCLC stage I to IIIA treated by surgical resection. There were no significant differences among the MTVs calculated by various threshold values of SUV (2.5, 3.0, 3.5, and 4.0). We expected that MTV using the lowest threshold value of 30% SUVmax would be an independent prognostic factor for the RFS in lung adenocarcinoma patients. In our study, TLG 30% showed the largest AUC among the AUCs of SUVmax, MTVs, and TLGs. In the MTV 30% model, MTV 30% showed marginal significance (p = 0.059). TLG 30% was an independent predictor for RFS; it showed a larger Fig. 2 Recurrence-free survival rate a in entire study population and recurrence-free survival rate base on b MTV 30% > 11.07 and MTV 30% ≤ 11.07 and c TLG 30% > 30.56 and TLG 30% ≤ 30.56 AUC compared with MTV 30% . This result was consistent with the findings of a previous study [12] . Our data demonstrated that TLG was a significant prognostic factor not only for stage IA lung adenocarcinoma but also for up to stage IIIA patients treated by surgical resection. Although TLG was an independent prognostic factor for RFS in lung adenocarcinoma stage I to IIIA treated by surgical resection, SUVmax and MTV remain useful parameters for prediction recurrence, and this was demonstrated in previous studies involving a large number of lung adenocarcinoma patients treated by surgical resection. This study has limitations. First, it was a retrospective, singlecenter study with a relatively small population by single PET/ CT equipment. Further study of a larger number of patients and comparison study with other PET/CT equipment are needed to confirm whether TLG is a better predictive factor. Also, in this study, the overall survival observation period was not long enough. Therefore, a relatively long follow-up observation period should be considered for long-term survival analysis. Despite these limitations, this present study provides meaningful results by analyzing volume-based parameters using a threshold value of 30% of SUVmax for predicting RFS in stage I to IIIA lung adenocarcinoma treated by surgical resection.
Conclusion
High TLG 30% was observed to be a significant risk factor for low RFS in patients treated using surgical resection for stage I to IIIA lung adenocarcinoma. Patients with high TLG 30% at the preoperative PET study should be closely observed for recurrence.
Compliance with Ethical Standards
Conflict of Interest Sunju Choi, Hye Ryeong Kwon, Hee Young Cho, Kisoo Pahk, Sung-Ho Lee, Jae-Ho Chung, Hyun Woo Kwon, and Sungeun Kim declare that they have no conflict of interest.
Ethical Statement All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000.
Informed Consent
The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.
